While TGFβ inhibitors are currently not used in the standard-of-care cancer treatment (48), there are numerous EGFR inhibitors used in cancer care, including the anti-EGFR mAb, cetuximab, which is FDA approved for the management of HNSCC (49). Here, TGFB1 is linked to head and neck squamous cell carcinoma.